Key Highlights:
Regulatory Progress:
Achieved positive clinical study results from the AD04-103 pharmacokinetics (PK) study supporting AD04's pharmacologic profile and regulatory strategy.
Received a positive response from the U.S. Food and Drug Administration (FDA) regarding the Company's proposed in vitro bridging strategy.
Successfully completed its End-of-Phase 2 (EOP2) meeting, advancing regulatory alignment toward Phase 3 development.
Expanded Intellectual Property Portfolio:
Strengthened IP coverage with multiple U.S. patents issued covering genotype-specific treatment of opioid disorders and expanded genetic-based approaches for treating and diagnosing Alcohol Use Disorder (AUD) and other dependencies.
Filed a Patent Cooperation Treaty (PCT) application to protect core assets and extend international exclusivity by 14 years through at least 2045.
Strategic Partnerships & Development Support:
Engaged Cytel Inc., a global leader in advanced clinical trial design and statistical methodologies, to support AD04 Phase 3 planning.
Partnered with Genomind to implement precision medicine testing solutions aligned with genotype-guided therapeutic strategy.
U.S.-Based Manufacturing Secured:
Secured U.S. manufacturing supply partnerships with Cambrex and Thermo Fisher Scientific for drug substance and drug product supply in support of late-stage development and future commercialization readiness.
"2025 was a pivotal year for Adial as we continued to advance AD04 scientifically, strategically, and within an evolving regulatory landscape," said Cary Claiborne, Chief Executive Officer of Adial Pharmaceuticals. "Our positive AD04-103 pharmacokinetic results, productive End-of-Phase 2 meeting with the FDA, and supportive FDA feedback on our in vitro bridging strategy provided meaningful validation of our clinical and regulatory approach. Engaging Cytel for advanced statistical design and partnering with Genomind for precision medicine testing further strengthens our ability to execute a rigorous and clinically relevant Phase 3 program."
"We were also encouraged by concurrent government and policy developments that align with the scientific rationale and real-world relevance of our development strategy. Bipartisan support in the U.S. Senate for expanding clinical trial endpoints beyond strict abstinence, including outcomes such as reduced cravings and disorder severity, reflects a more patient-centered approach to evaluating addiction therapeutics, consistent with how AD04 is designed to benefit patients. Such support was underscored by a Congressional directive advancing alternative clinical trial endpoints for substance use disorders, which strengthens the regulatory path forward for AD04 and reinforces the importance of broader, clinically meaningful measures in AUD development."
"In addition, recent FDA policy discussion indicating that, in certain scientifically justified cases, approval may be supported by one adequate and well-controlled study plus confirmatory evidence, rather than two independent pivotal trials, highlights a potential shift toward more flexible yet scientifically robust development frameworks. Because Phase 3 trials represent the most capital-intensive stage of development, the ability to pursue a single well-designed pivotal study instead of two could potentially reduce late-stage clinical development costs by tens of millions of dollars, while also lowering associated site, CRO, and operational expenses. A one-study framework could materially improve capital efficiency and shorten development timelines by eliminating the need to initiate and complete a second confirmatory trial, thereby accelerating our potential path toward NDA submission."
"Taken together, these scientific validations, regulatory discussions, and governmental policy signals reinforce the strength of our strategy and the relevance of AD04's precision medicine approach. With an expanded intellectual property estate, key strategic partnerships, and ...
